Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.47 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097172 | 0.93 | AGTR2 (0.51) | PREPAGTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9132544 | 0.83 | NPC1 (0.54) | PREPKLK7KLK5NPC1RAB9A | |
| SCHEMBL27190405 | 0.83 | SMN1; SMN2 (0.52) | PREPNPC1RAB9ASMN1; SMN2ACE2 | |
| SCHEMBL29239602 | 0.83 | SMN1; SMN2 (0.52) | PREPNPC1RAB9ASMN1; SMN2ACE2 | |
| SCHEMBL27190317 | 0.83 | SMN1; SMN2 (0.52) | PREPNPC1RAB9ASMN1; SMN2ACE2 | |
| SCHEMBL31097140 | 0.79 | PREP (0.48) | PREPAGTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10201272 | 0.78 | PREP (0.53) | PREPACE2 | |
| SCHEMBL27190401 | 0.78 | PREP (0.53) | PREPACE2 | |
| SCHEMBL31097167 | 0.78 | SMN1; SMN2 (0.50) | PREPAGTR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31097194 | 0.78 | SMN1; SMN2 (0.50) | PREPAGTR2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | PREP 182/4885AGTR2 1541/4885KLK7 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.